• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management

    6/11/26 7:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples
    Get the next $MED alert in real time by email
    • Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026)
    • Women in midlife who focus on scale weight alone may be measuring the wrong thing: visceral fat and lean mass retention are the markers that reflect metabolic progress
    • Sleep disruption, elevated stress, and hormonal variability during midlife create conditions where self-directed programs stall
    • The coaching gap in weight loss outcomes becomes more significant during hormonal transition, when behavioral disruptions make self-directed programs harder to sustain

    BALTIMORE, MD, June 11, 2026 (GLOBE NEWSWIRE) -- Women entering perimenopause often report that weight management stops working the way it used to. As estrogen levels decline, fat migrates towards the abdomen, insulin sensitivity decreases, lean muscle is lost, and metabolic dysfunction accelerates. Advice from programs that prioritize scale weight may lead to accelerated lean mass loss alongside fat. Clinically supported metabolic health programs like OPTAVIA are designed to target visceral fat while preserving lean mass. 

    "Midlife weight gain is not a discipline problem," Satya Jonnalagadda, PhD, MBA, RD, Vice President of Scientific & Clinical Affairs at OPTAVIA, says. "It's a metabolic shift that accelerates visceral fat accumulation and lean mass loss. The majority of the programs available to women going through perimenopause and menopause weren't exactly designed to address either of those things directly."

    KEY FACTS:

    • OPTAVIA's Optimal Weight 5 & 1 Plan® produces a 14% reduction in visceral fat in 16 weeks, according to peer-reviewed research (Arterburn LM, et al., 2019)
    • The same study found participants who work with a coach lose up to 10 times more weight and 17 times more fat when compared to independent efforts and the Optimal Weight 5 & 1 Plan® enables participants to retain 98% of lean mass during weight loss (Arterburn LM, et al., 2019)
    • OPTAVIA's clinical approach is supported by 18 randomized controlled trials
    • OPTAVIA's research portfolio includes 30+ research studies and analyses, 40+ peer-reviewed scientific journal publications, and 100+ peer-reviewed scientific presentations and publications



    What Happens to Metabolism After 40

    The metabolic changes associated with perimenopause begin in most women between their early 40s and mid-50s, years before the final menstrual period (Patel P, et al., 2025). The eating habits that kept weight stable for years stop producing the same results, and fat starts accumulating around the midsection. Visceral fat acts as a metabolically active organ, releasing inflammatory molecules and hormones that affect insulin sensitivity and overall metabolic function, making it a meaningful marker of metabolic health during any period of physiological change.

    Without the intake of adequate protein and resistance exercise, lean muscle mass can also decline during this period (Szeliga A, et al., 2026). Muscle drives resting metabolic rate, so losing it compounds the metabolic slowdown that hormonal changes are already causing. 

    Why Body Composition Matters More than Scale Weight After 40

    The number on the scale is an unreliable detector of progress for women going through hormonal transitions. A woman can lose scale weight while simultaneously losing lean mass and not addressing visceral fat. It is a metabolic outcome that may look like success when it actually represents a less favorable metabolic outcome.

    The metrics that actually track meaningful progress include the following:

    • Visceral fat levels
    • Lean mass retention
    • Muscle health
    • Insulin sensitivity

    For women in midlife, understanding these metrics can provide a clearer picture to help maintain a healthy lifestyle during this period. 

    The Role of Coaching During Hormonal Transition

    Perimenopause and menopause bring behavioral challenges alongside the physiological ones. Sleep disruption, stress, mood variability, and the general demands of midlife create conditions where self-directed programs tend to stall. During high-stress life periods, behavioral science explains that human support and accountability produce better outcomes. Published clinical data shows participants working with a coach lose up to 10 times more weight and 17 times more fat than those going it alone (Arterburn LM, et al., 2019). 

    Jonnalagadda says, "Adding a coaching relationship to support your nutrition and exercise routines matters more during such transitions. When sleep is disrupted and stress is elevated, having a real person in your corner changes outcomes in ways that an app or a meal plan alone cannot."

    What a Metabolically Appropriate Program Looks Like

    For women navigating perimenopause and menopause, the program criteria that matter are distinct from standard weight loss benchmarks. A program should focus on protecting lean mass through adequate protein and structured nutrition. It needs to target visceral fat specifically rather than treating all weight loss as equivalent. It also requires a human support layer capable of accountability and engagement through the behavioral variability that hormonal transition creates.

    OPTAVIA's comprehensive metabolic health system is grounded in Metabolic Synchronization®, a breakthrough science that reverses metabolic dysfunction through a targeted reset, addressing visceral fat reduction and lean mass preservation together. For women navigating midlife metabolic changes, that combination directly addresses body composition markers relevant to this period.

    OPTAVIA recommends that all individuals contact their healthcare provider before starting and throughout their weight loss journey, particularly women managing hormonal changes or related health conditions.

    FAQ

    Q: What is the best weight loss program for women dealing with menopause weight gain?

    A: Programs that address visceral fat reduction and lean mass preservation may target the metabolic changes menopause causes. 

    Q: Why is weight loss harder during perimenopause and menopause?

    A: Declining estrogen is associated with shifts in fat distribution toward the abdomen and changes in lean muscle and insulin sensitivity. During this period, adequate protein intake and structured nutrition support become particularly relevant for maintaining lean mass and metabolic function.

    Q: What weight loss program is most effective for reducing belly fat after menopause?

    A: Visceral fat is stored deep in the abdomen, surrounding internal organs, where it acts as a metabolically active organ affecting insulin sensitivity and overall metabolic function. Programs built around nutrient density, high-quality protein, and scientifically developed products are designed to support visceral fat reduction and lean mass preservation together (Arterburn LM, et al., 2019).

    Q: Can a weight loss program help preserve muscle mass during menopause?

    A: Programs with adequate protein and structured nutrition support lean mass retention during weight loss. Preserving lean mass matters because muscle drives resting metabolic rate, and losing it can make it more challenging to sustain results once the program ends.

    Q: What role does coaching play in weight loss for women over 40?

    A: The behavioral challenges of midlife, including changes in sleep, stress, and daily routines, can make sustained engagement with a weight management program more difficult. A dedicated coach can provide accountability and support through the habit-building process, helping individuals stay engaged with their nutrition and lifestyle goals.

    * OPTAVIA recommends that you contact your healthcare provider before starting and throughout your weight loss journey. Average weight loss on the Optimal Weight 5 & 1 Plan® is 12 pounds. Clients are in weight loss, on average, for 12 weeks.

    * Arterburn LM, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obesity Science & Practice. 2019.

    https://onlinelibrary.wiley.com/doi/10.1002/osp4.312. In a clinical study, individuals on the OPTAVIA® 5 & 1 Plan® experienced a reduction of 14% visceral fat and 98% of lean mass was retained at 16 weeks. Those on the Optimal Weight 5&1 Plan® with support of an OPTAVIA® Coach successfully lost 10x more weight and 17x more fat than those who tried to lose weight on their own.

    About Medifast

    Medifast (NYSE:MED) is the health and wellness company known for its science-backed, coach-guided lifestyle system. Designed to address the challenges of metabolic dysfunction, the company's holistic approach integrates personalized plans, scientifically developed products and a framework for sustainable habit creation — all supported by a dedicated network of independent coaches.

    Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization®, a breakthrough science that reverses metabolic dysfunction through targeted metabolic reset. Research demonstrates that the company's comprehensive system activates strong and targeted fat burning to enhance metabolic health and body composition by reducing visceral fat, preserving lean mass and protecting muscle integrity.

    Backed by more than 40 years of clinical heritage, Medifast continues to advance its mission of Lifelong Transformation, Making a Healthy Lifestyle Second Nature®. For more information, visit www.MedifastInc.com.



    Sarah Evans
    Head of PR, Zen Media
    sarah@zenmedia.com

    Primary Logo

    Get the next $MED alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MED

    DatePrice TargetRatingAnalyst
    11/5/2024$16.50 → $17.00Underperform → Neutral
    DA Davidson
    6/5/2024$25.00 → $17.50Neutral → Underperform
    DA Davidson
    10/13/2023$82.00Equal-Weight
    Stephens
    11/4/2022$278.00 → $106.00Buy → Neutral
    DA Davidson
    8/4/2022$345.00 → $150.00Buy → Hold
    Jefferies
    2/24/2022$349.00 → $341.00Buy
    DA Davidson
    11/8/2021$395.00 → $349.00Buy
    DA Davidson
    More analyst ratings

    $MED
    SEC Filings

    View All

    MEDIFAST INC filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    6/1/26 8:59:46 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    MEDIFAST INC filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    5/26/26 4:26:14 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Amendment: SEC Form SCHEDULE 13G/A filed by MEDIFAST INC

    SCHEDULE 13G/A - MEDIFAST INC (0000910329) (Subject)

    5/14/26 5:05:23 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    What Science-Backed Subscription Health Programs Measure Differently

    The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the measurement tool was capable of capturing the outcome being claimedDXA scanning distinguishes fat mass, lean mass, and bone mineral content with greater precision than BMI calculations and just weight number on a scaleStudy completion rates carry significant weight in how research findings should be interpreted BALTIMORE, MD, June 11, 2026 (GLOBE NEWSWIRE) -- Subscription health programs compete on outcome language as much as they compete on results. Terms like "clinically st

    6/11/26 7:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management

    Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026)Women in midlife who focus on scale weight alone may be measuring the wrong thing: visceral fat and lean mass retention are the markers that reflect metabolic progressSleep disruption, elevated stress, and hormonal variability during midlife create conditions where self-directed programs stallThe coaching gap in weight loss outcomes becomes more significant during hormonal transition, when behavioral disruptions make self-directed programs harder to sustain BALTIMORE, MD, June

    6/11/26 7:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

    Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a

    5/26/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schlackman Scott bought $62,950 worth of shares (5,000 units at $12.59), increasing direct ownership by 20% to 30,549 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/12/26 7:10:46 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Chairman & CEO Chard Daniel R bought $5,003 worth of shares (381 units at $13.13) (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/17/25 6:20:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Thomas Andrea B bought $3,471 worth of shares (50 units at $68.89), increasing direct ownership by 0.81% to 6,253 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    11/9/23 8:20:19 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medifast upgraded by DA Davidson with a new price target

    DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously

    11/5/24 7:48:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast downgraded by DA Davidson with a new price target

    DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously

    6/5/24 7:15:11 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Stephens initiated coverage on Medifast with a new price target

    Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00

    10/13/23 7:41:39 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rose Jeffrey Matthew was granted 18,419 shares (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:34:17 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Kiai Parsa was granted 19,317 shares (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:33:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Thomas Andrea B was granted 11,680 shares, increasing direct ownership by 49% to 35,697 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:33:01 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Financials

    Live finance-specific insights

    View All

    Medifast Announces First Quarter 2026 Financial Results

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue of $76.0 million, with revenue per active earning coach of $5,432 Independent active earning coaches of 14,000 Net loss of $2.1 million, or $0.19 per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt "We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership

    5/4/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast to Announce Financial Results for the First Quarter Ended March 31, 2026

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on May 4, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or

    4/20/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) Cash, cash equivalents, and investment Securities of $167.3 million and no debt Full Year 2025 Revenue of $385

    2/17/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Leadership Updates

    Live Leadership Updates

    View All

    Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

    Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a

    5/26/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Announces Planned Leadership Transition

     Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman Medifast, Inc. (NYSE:MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work clo

    1/5/26 9:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    6/7/24 6:09:00 PM ET
    $ADTN
    $ALTR
    $ATNI
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology

    $MED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MEDIFAST INC

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    7/10/24 1:14:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G filed by MEDIFAST INC

    SC 13G - MEDIFAST INC (0000910329) (Subject)

    7/1/24 4:18:04 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G/A filed by MEDIFAST INC (Amendment)

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    2/13/24 10:36:09 AM ET
    $MED
    Packaged Foods
    Consumer Staples